Anti-Hypertensive Drugs - Northern Africa

Northern Africa

The revenue in the Anti-Hypertensive Drugs market is estimated to reach US$62.39m in 2024 in Northern AfriIt is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 0.46%, leading to a market volume of US$63.83m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$12,290.00m in 2024.
In Northern Africa, there is a growing demand for locally produced anti-hypertensive drugs due to increasing healthcare awareness.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Northern Africa is on the rise due to various factors.

Customer preferences: Customers in Northern Africa are becoming increasingly health-conscious and aware of the risks associated with hypertension. As a result, they are more willing to seek medical attention and take medication to manage their blood pressure. Additionally, the aging population in the region is also driving demand for anti-hypertensive drugs.

Trends in the market: The market for anti-hypertensive drugs in Northern Africa is expected to grow steadily in the coming years. This growth can be attributed to the increasing prevalence of hypertension in the region, as well as the rising demand for healthcare services. Additionally, the growing availability of generic drugs is also expected to contribute to the growth of the market.

Local special circumstances: One of the unique factors that affect the anti-hypertensive drugs market in Northern Africa is the prevalence of traditional medicine. Many people in the region still rely on traditional remedies to manage their health, and this can sometimes lead to a reluctance to take western medication. Additionally, the high cost of medication can also be a barrier to access for some patients.

Underlying macroeconomic factors: The healthcare sector in Northern Africa is undergoing significant development, with many countries investing in the expansion and modernization of their healthcare systems. This is expected to drive demand for anti-hypertensive drugs, as more people gain access to healthcare services. Additionally, the region's growing population and increasing urbanization are also expected to contribute to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.